EN DE
STOCK COMPARISON

Korea Pharmacy Co. vs Merck & Company: Fair Value & Quality

Both stocks run through our valuation models. Here is how Korea Pharmacy Co. (032300) and Merck & Company (MRK) compare, as of Sep 14, 2026.

As of Sep 14, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Korea Pharmacy Co. trades at KRW 7,620 versus a fair value of KRW 2,527 (-67%), while Merck & Company trades at $144 versus $125 (-13%).
Korea Pharmacy Co.
032300.KQ · KRW · Energy
-67%
upside to fair value
overvalued
PriceKRW 7,620
Fair ValueKRW 2,527
Quality46/100
Merck & Company
MRK · USD · Health Care
-13%
upside to fair value
overvalued
Price$144
Fair Value$125
Quality70/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Korea Pharmacy Co.Merck & Company
Valuation
P/E (TTM)43.5×
P/S (TTM)4.64×
P/B5.80×
EV/EBITDA11.4×
PEG6.10×
−66.8%Fair value upside−12.9%
0.6%Dividend yield2.2%
KRW 50Dividend per share$3.28
Profitability
5%Operating margin39%
EBIT margin trend (5Y)2.70×
-4%Return on equity19%
-0%Return on assets13%
Growth
18%Revenue growth (YoY)5%
2.6%Avg. growth/yr (3Y)3.1%
4.1%Avg. growth/yr (5Y)9.4%
Value creation/yr+16.0%
Balance & size
Interest coverage (EBIT/interest)17.3×
0.27×Debt / equity0.89×
$57MMarket cap$305B
mixedGrowth qualityhealthy
Valuation multiples (P/E, P/S, P/B, EV/EBITDA) are shown but not scored here: the two companies sit in different sectors, and multiples only compare fairly between similar business models. PEG stays scored, as it relates the P/E to growth.

Merck & Company leads: 1 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Korea Pharmacy Co.of which business quality 46 · market factors 25 Merck & Companyof which business quality 68 · market factors 87
ProfitabilityMargins and returns on capital today
22
74
Quality GrowthAre margins and returns improving?
19
36
CashflowEarnings quality: real cash, not paper profit
24
65
Fin. StrengthBalance sheet, leverage, solvency risk
63
68
InvestmentDisciplined investing over empire-building
92
71
Low VolatilityCalm price path (market factor)
65
83
MomentumPrice trend over the last 3–12 months (market factor)
12
82
52W MomentumDistance to the 52-week high (market factor)
3
100
Net IssuanceShare count: buybacks or dilution?
82
91

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyKorea Pharmacy Co.Price KRW 7,620Merck & CompanyPrice $144
DCF Models-67%below the priceKRW 2,507-19%below the price$117
Earnings-Basedn/a-56%below the price$62.77
Dividend Discountn/a-58%below the price$60.35
Multiples-70%below the priceKRW 2,258-15%below the price$122
Asset-Based-45%below the priceKRW 4,226-90%below the price$14.27
Growth DCF-65%below the priceKRW 2,637-49%below the price$74.00
Economic Profitn/a-42%below the price$83.85
Growth Earningsn/a-4%close to the price$138
Minimum-70%below the priceKRW 2,258-90%below the price$14.27
Maximum-45%below the priceKRW 4,226-4%close to the price$138
Median-66%below the priceKRW 2,572-45%below the price$78.93
Geometric mean-63%below the priceKRW 2,818-50%below the price$71.25

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Korea Pharmacy Co.: 10 of 10 models see the stock below the current price.

Merck & Company: 23 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Korea Pharmacy Co.
Price KRW 7,620
Fair Value KRW 2,527
Bear KRW 1,985Bull KRW 3,162
Merck & Company
Price $144
Fair Value $125
Bear $70.92Bull $188

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Korea Pharmacy Co. · Energy

Quality score46 · below median
Fair value upside-67% · bottom 25%

Merck & Company · Health Care

Quality score70 · Top 25%
Fair value upside-13% · above median

Bottom line

As of Sep 14, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Korea Pharmacy Co. trades at KRW 7,620 versus a fair value of KRW 2,527 (-67%), while Merck & Company trades at $144 versus $125 (-13%).

Merck & Company has the higher quality score (70/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.